ZM323881 hydrochloride (HCL) is a selective inhibitor of the epidermal growth factor receptor (EGFR), which plays a critical role in cancer cell proliferation, survival, and metastasis. It is primarily used for the treatment of certain types of cancer, including non-small cell lung cancer and pancreatic cancer.
Chemical Name: N-[3-chloro-4-(2-pyridylmethoxy)phenyl]-6-[5(1-methylpiperidin-4-yl)-1H-benzimidazol-2-yl]quinazolin-4-amine hydrochloride
Molecular Formula: C33H32ClN7O
Formula Weight: 580.11 g/mol
CAS No: 193000-39-4
Top ten keywords from Google:
Synonyms: ZM-323881; ZM 323881; NVP-AEE788; AEE788; 869357-68-6
Health benefits of this product:
ZM323881 has been shown to have potent anti-cancer properties, particularly against solid tumors such as non-small cell lung cancer and pancreatic cancer. It works by inhibiting the activity of EGFR tyrosine kinase, which promotes cell proliferation and survival in cancer cells. By blocking this pathway, ZM323881 can slow down or even stop cancer progression.
In addition to its anti-cancer effects, ZM323881 may also have potential therapeutic applications in other conditions that involve abnormal EGFR activity, such as psoriasis and rheumatoid arthritis. It has also been studied for its potential use in glioblastoma, a type of brain cancer.
ZM323881 is a competitive inhibitor of the EGFR tyrosine kinase, which is a key mediator of cancer cell proliferation and survival. When EGFR binds to its ligand, it triggers a signaling cascade that promotes cell growth and survival. By blocking this pathway, ZM323881 can inhibit the activity of EGFR and prevent cancer cell growth and metastasis.
Like all medications, ZM323881 can have potential safety concerns. It has been associated with serious adverse events such as thrombosis, bleeding, and cardiovascular complications. Patients taking ZM323881 should be closely monitored for signs of these complications. Additionally, ZM323881 should not be used in pregnant women or patients with severe liver or kidney dysfunction.
Common side effects of ZM323881 include fatigue, diarrhea, skin rash, and nausea. Patients may also experience mucositis or peripheral neuropathy. More serious side effects such as congestive heart failure, pulmonary embolism, and cerebral hemorrhage have also been reported.
ZM323881 is typically administered orally at a dose of 50-500 mg per day depending on the patient's response and disease status. The treatment course may last up to six months or longer. Dosing adjustments may be necessary based on the patient's age, body weight, and renal or hepatic function.
ZM323881 is a promising anti-cancer drug that works by inhibiting the activity of EGFR tyrosine kinase. While it has shown efficacy in clinical trials for certain types of cancer, it also carries potential risks and side effects that must be carefully considered. Further research is needed to determine its optimal dosing and long-term safety profile, as well as explore its potential therapeutic applications in other disease contexts